share_log

Brookline Capital Initiates Coverage On Palisade Bio With Buy Rating, Announces Price Target of $38

Brookline Capital Initiates Coverage On Palisade Bio With Buy Rating, Announces Price Target of $38

Brookline Capital啓動了對Palisade Bio的買入評級,宣佈目標股價爲38美元
Benzinga ·  2024/11/21 06:00  · 評級/大行評級

Brookline Capital analyst Kumaraguru Raja initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $38.

布魯克林資本分析師庫馬拉古魯·拉賈以買入評級啓動了對Palisade Bio(納斯達克股票代碼:PALI)的報道,並宣佈目標股價爲38美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論